CD274 and cancer: However, for a specific group of cancers (e.g., non-small cell lung cancer), evidence suggests that responsiveness to PD-1 inhibitors such as pembrolizumab and nivolumab or to the anti-PD-L1 antibodies atezolizumab and durvalumab may be predicted by expression of PD-L1 on TCs and/or tumor-infiltrating immune cells (ICs) [1].